Excelsior Sciences
New York · Founded 2024
About Excelsior Sciences
Excelsior Sciences develops a chemistry and AI platform for discovering and manufacturing small-molecule compounds. It uses a proprietary “smart bloccs” system, which consists of modular, machine-ready chemical building blocks, to convert small-molecule innovation into an iterative, automation-friendly workflow. Through this platform, Excelsior enables closed-loop cycles of AI-guided synthesis, testing, and optimisation that link early-stage discovery to scalable manufacturing. The company supports projects across pharmaceuticals, materials science, and other sectors that rely on small molecules. Excelsior also maintains an internal pipeline of therapeutic candidates while working with partners to deploy its chemistry platform broadly.
Company Facts
- Founded: 2024
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $95.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2025)
- Website: https://www.excelsiorsci.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/excelsior-sciences-48874 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.